![](https://eurekare.eu/wp-content/uploads/2023/05/Cover-eureKING-Skyepharma-300x169.png)
eureKING, the first European SPAC in healthcare dedicated tobiomanufacturing, announces the signature of a put option for thepotential acquisition of Skyepharma to build a new European bio-CDMO leader
The proposed transaction would represent the first cornerstone of eureKING’s project to pursue bolt-on acquisitions to add innovative companies from the fast growing biotherapies CDMO segment to its platform to create a bio-CDMO leader and which could result in additional transactions. These transactions may be announced before the completion of the proposed transaction.